Tongling Jieya Biologic Technology Co (301108) Fair Value & Analysis
Consumer Defensive · CN · Market cap 2.8B CNY
Fair value as of: Jul 9, 2026
From 14 valuation models · updated 32 days ago
Share price +24.9% over the past month.
A solid business, but screening 72% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥13.40). The favourable scenario is already priced in.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
56‑month range ¥20.99 – ¥78.99 · fair‑value band ¥9.19 – ¥13.40 · the ¥38.15 price screens above the ¥10.87 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Tongling Jieya Biologic Technology Co (301108) currently trades at ¥38.15, while our model-based Fair Value estimate is ¥10.87, implying the stock looks roughly 71.5% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Tongling Jieya Biologic Technology Co generated revenue of 841M CNY at a net margin of 9.2%. Revenue grew 55.5% year over year. It earns a return on equity of 4.2%. The stock trades on a trailing P/E of 39.2. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥9.19 (bear case) to ¥13.40 (bull case); at ¥38.15, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 80% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -72%, 301108 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (¥14.42) versus Earnings-Based (¥3.43). Highest evidence: Residual Income (76).
Notify me when 301108 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tongling Jieya Biologic Technology Co., Ltd. engages in the research and development, production, and sales of wet wipe products in China. It offers baby, adult functional, antibacterial and disinfection, household clearing, medical care, pet cleaning wipes, wet toilet papers.
Full company description
Tongling Jieya Biologic Technology Co., Ltd. engages in the research and development, production, and sales of wet wipe products in China. It offers baby, adult functional, antibacterial and disinfection, household clearing, medical care, pet cleaning wipes, wet toilet papers. The company also provides beauty care products, such as emollient water, Lotion, Cream, Essence, Membranes, clean, Body Series, Children's series, and Hair series, as well as facial masks and cleaning products. Tongling Jieya Biologic Technology Co., Ltd. was founded in 1999 and is based in Tongling, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tongling Jieya Biologic Technology Co reported revenue of ¥772M in FY2025 versus ¥984M in FY2021, a compound −5.9%/yr. Reported net income was ¥77.3M in FY2025, compounding −23.0%/yr from FY2021.
301108 screens 72% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Tongling Jieya Biologic Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Tongling Jieya Biologic Technology Co (301108) overvalued or undervalued?
What is the fair value of 301108?
What is the quality score of 301108?
What is the revenue of Tongling Jieya Biologic Technology Co (301108)?
What is the net profit margin of 301108?
Does Tongling Jieya Biologic Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tongling Jieya Biologic Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.